Trontinemab (RG6102) is a monoclonal antibody (mAb) developed by Roche/Genentech for the treatment of Alzheimer's disease. It is based on gantenerumab, an anti-amyloid monoclonal antibody, and uses a brainshuttle domain to enhance its permeability through the blood–brain barrier.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.